Effect of adding selegiline to levodopa in early, mild Parkinson's disease [1]

British Medical Journal

Volumn 312, Issue 7032, 1996, Pages 702-705

  Maki Ikola, O ^a   Kilkku, O ^a   Heinonen, E ^a   Anderson, K E ^a   Girdwood, A C ^a   Wilson, J A ^a   Olanow, C W ^a   Godbold, J H ^a   Koller, W ^a   MacMahon, D G ^a   Bland, R ^a   Silva, M T ^a   Watts, P M ^a   Jenner, P ^a   Lees, A J ^a   Head, J ^a   Ben Shlomo, Y ^a  

^a ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

CAUSE OF DEATH; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; META ANALYSIS; NOTE;

ANTIPARKINSON AGENTS; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; META-ANALYSIS; PARKINSON DISEASE; SELEGILINE;

EID: 0029916818     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (0)